Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more
Bolt Biotherapeutics (BOLT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.303x
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) has a cash flow conversion efficiency ratio of -0.303x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.73 Million) by net assets ($32.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bolt Biotherapeutics - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Bolt Biotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bolt Biotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bolt Biotherapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Freightos Limited Warrants
NASDAQ:CRGOW
|
-0.069x |
|
Tong Hua Holding Public Company Limited
BK:TH
|
0.002x |
|
Onxeo S.A.
LSE:0NWK
|
N/A |
|
Tonner Drones S.A.
PA:ALTD
|
N/A |
|
PARKER-HANNIFIN CO. - Dusseldorf Stock Exchang
DU:PAR
|
0.058x |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
0.313x |
|
Equites Property Fund Ltd
JSE:EQU
|
0.035x |
|
Nureca Limited
NSE:NURECA
|
0.022x |
Annual Cash Flow Conversion Efficiency for Bolt Biotherapeutics (2018–2024)
The table below shows the annual cash flow conversion efficiency of Bolt Biotherapeutics from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.20 Million | $-61.29 Million | -1.072x | -73.76% |
| 2023-12-31 | $112.74 Million | $-69.53 Million | -0.617x | -38.25% |
| 2022-12-31 | $171.51 Million | $-76.50 Million | -0.446x | -95.51% |
| 2021-12-31 | $250.12 Million | $-57.07 Million | -0.228x | -150.61% |
| 2020-12-31 | $-104.95 Million | $-47.31 Million | 0.451x | -21.55% |
| 2019-12-31 | $-45.85 Million | $-26.34 Million | 0.575x | -7.20% |
| 2018-12-31 | $-15.94 Million | $-9.87 Million | 0.619x | -- |